Legal & General Group PLC Alnylam Pharmaceuticals, Inc. Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

A detailed history of Legal & General Group PLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 960,959 shares of ALNY stock, worth $233 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

960,959

Previous 960,959 -0.0%

Holding current value

$233 Million

Previous $264 Million -0.0%

% of portfolio

0.06%

Previous 0.06%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$233.81 - $287.01 $8.1 Million - $9.94 Million	34,629 Added 3.74%	960,959 $264 Million
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $735,896 - $1.27 Million	5,135 Added 0.56%	926,330 $225 Million
Q1 2024 May 14, 2024	SELL	$146.51 - $198.2 $1.43 Million - $1.93 Million	-9,744 Reduced 1.05%	921,195 $138 Million
Q4 2023 Feb 15, 2024	BUY	$151.41 - $196.57 $20.6 Million - $26.8 Million	136,268 Added 17.15%	930,939 $178 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $634,922 - $786,914	-3,718 Reduced 0.47%	794,671 $141 Million
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $12.5 Million - $14.3 Million	67,367 Added 9.22%	798,389 $152 Million
Q1 2023 May 15, 2023	SELL	$182.66 - $235.53 $243,485 - $313,961	-1,333 Reduced 0.18%	731,022 $146 Million
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $4.11 Million - $5.34 Million	-22,137 Reduced 2.93%	732,355 $174 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $3.39 Million - $5.67 Million	-24,456 Reduced 3.14%	754,492 $151 Million
Q2 2022 Aug 22, 2022	BUY	$120.42 - $169.29 $2.59 Million - $3.64 Million	21,526 Added 2.84%	778,948 $114 Million
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $9.9 Million - $13.5 Million	77,852 Added 11.46%	757,422 $124 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $2.04 Million - $2.68 Million	12,785 Added 1.92%	679,570 $115 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $2.82 Million - $3.45 Million	-16,625 Reduced 2.43%	666,785 $126 Million
Q2 2021 Aug 12, 2021	BUY	$128.63 - $176.89 $4.76 Million - $6.54 Million	36,972 Added 5.72%	683,410 $116 Million
Q1 2021 May 17, 2021	BUY	$126.83 - $175.69 $135,200 - $187,285	1,066 Added 0.17%	646,438 $91.3 Million
Q4 2020 Feb 12, 2021	BUY	$122.97 - $147.0 $1.79 Million - $2.14 Million	14,580 Added 2.31%	645,372 $83.9 Million
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $276,797 - $377,979	-2,284 Reduced 0.36%	630,792 $91.8 Million
Q2 2020 Aug 14, 2020	BUY	$104.21 - $156.44 $3.07 Million - $4.61 Million	29,439 Added 4.88%	633,076 $93.8 Million
Q1 2020 May 14, 2020	BUY	$93.12 - $133.99 $2.75 Million - $3.96 Million	29,567 Added 5.15%	603,637 $65.7 Million
Q4 2019 Feb 13, 2020	BUY	$74.51 - $124.23 $3.04 Million - $5.07 Million	40,774 Added 7.65%	574,070 $66.1 Million
Q3 2019 Nov 13, 2019	BUY	$70.9 - $87.82 $2.29 Million - $2.84 Million	32,349 Added 6.46%	533,296 $42.9 Million
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $1.74 Million - $2.45 Million	26,365 Added 5.56%	500,947 $36.3 Million
Q1 2019 May 15, 2019	BUY	$72.76 - $93.45 $7.83 Million - $10.1 Million	107,682 Added 29.35%	474,582 $44.3 Million
Q4 2018 Feb 15, 2019	BUY	$62.67 - $88.33 $1.69 Million - $2.38 Million	26,958 Added 7.93%	366,900 $26.8 Million
Q3 2018 Nov 20, 2018	SELL	$87.52 - $122.67 $49,798 - $69,799	-569 Reduced 0.17%	339,942 $29.8 Million
Q2 2018 Aug 10, 2018	SELL	$88.31 - $107.8 $711,690 - $868,760	-8,059 Reduced 2.31%	340,511 $33.5 Million
Q1 2018 May 17, 2018	BUY	$115.92 - $148.54 $28.1 Million - $36 Million	242,098 Added 227.38%	348,570 $41.5 Million
Q4 2017 Feb 13, 2018	BUY	$114.49 - $139.98 $12.2 Million - $14.9 Million	106,472	106,472 $13.5 Million

Others Institutions Holding ALNY

# of Institutions

643

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Alnylam Pharmaceuticals, Inc. Transaction History